thalidomide has been researched along with Nervous System Disorders in 38 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is effective for treating the oral and genital ulcers and follicular lesions of the Behçet syndrome." | 9.08 | Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. ( Hamuryudan, V; Mat, C; Ozyazgan, Y; Saip, S; Siva, A; Yazici, H; Yurdakul, S; Zwingenberger, K, 1998) |
| "Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM)." | 7.80 | Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. ( Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S, 2014) |
| "Between April 2006 and June 2009, 34 newly diagnosed patients with multiple myeloma received one to three courses of bortezomib 1." | 7.76 | Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). ( Alexanian, R; Delasalle, K; Giralt, S; Wang, M, 2010) |
| "Grade 3/4 toxicities included neurological disorders (16%), nausea (12%), vomiting (8%), and thromboembolism (8%)." | 6.79 | Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. ( Aklilu, M; Fenstermaker, J; Levine, EA; McCoy, TP; Shen, P; Thomas, CR, 2014) |
| " We conducted a phase II, multicentre, study to investigate thalidomide in severely symptomatic indolent and aggressive systemic mastocytosis." | 5.17 | Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study. ( Barete, S; Bruneau, J; Canioni, D; Chaby, G; Chandesris, O; Damaj, G; Diouf, M; Dubreuil, P; Durieu, I; Grosbois, B; Gruson, B; Hermine, O; Lanternier, F; Larroche, C; Livideanu, C; Lortholary, O; Marolleau, JP; Sevestre, H, 2013) |
| "Thalidomide (Thal) can overcome drug resistance in multiple myeloma (MM) but is associated with somnolence, constipation, and neuropathy." | 5.10 | Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. ( Anderson, KC; Balinski, K; Catley, LP; Chauhan, D; Davies, F; Deocampo, R; Doss, D; Freeman, A; Hideshima, T; Kelly, K; LeBlanc, R; McKenney, M; Mechlowicz, J; Mitsiades, C; Rich, R; Richardson, PG; Ryoo, JJ; Schlossman, RL; Weller, E; Zeldis, J, 2002) |
| "Thalidomide is effective for treating the oral and genital ulcers and follicular lesions of the Behçet syndrome." | 5.08 | Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. ( Hamuryudan, V; Mat, C; Ozyazgan, Y; Saip, S; Siva, A; Yazici, H; Yurdakul, S; Zwingenberger, K, 1998) |
| "In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma: the proteasome inhibitor (PI) bortezomib (Velcade), the immunomodulatory agents lenalidomide (Revlimid) and thalidomide (Thalomid), and liposomal doxorubicin." | 4.87 | Treatment-related adverse events in patients with relapsed/refractory multiple myeloma. ( Vij, R, 2011) |
| "Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM)." | 3.80 | Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. ( Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S, 2014) |
| "Between April 2006 and June 2009, 34 newly diagnosed patients with multiple myeloma received one to three courses of bortezomib 1." | 3.76 | Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). ( Alexanian, R; Delasalle, K; Giralt, S; Wang, M, 2010) |
| "Grade 3/4 toxicities included neurological disorders (16%), nausea (12%), vomiting (8%), and thromboembolism (8%)." | 2.79 | Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. ( Aklilu, M; Fenstermaker, J; Levine, EA; McCoy, TP; Shen, P; Thomas, CR, 2014) |
| "Thalidomide has antiangiogenic and immunomodulatory properties and has recently been used in the management of human malignancies." | 2.43 | Thalidomide and immunomodulatory drugs in the treatment of cancer. ( Bamias, A; Dimopoulos, MA, 2005) |
| " The latter limit the long-term use of thalidomide and imply strict rules for its prescription and surveillance (efficient contraception, clinical neurological examinations, electroneurophysiological controls)." | 2.42 | [Management of a patient receiving thalidomide]. ( Brocvielle, H; Humbert, P; Kantelip, JP; Muret, P; Plenat, E, 2003) |
| "Thalidomide was later found to very effectively suppress erythema nodosum leprosum (ENL)." | 2.41 | Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. ( Clark, TE; Edom, N; Larson, J; Lindsey, LJ, 2001) |
| "Thalidomide is a second-line treatment for discoid lupus erythematosus (DLE)." | 1.62 | Clinical-therapeutic study on the efficacy and safety of thalidomide in the management of discoid lupus erythematosus. A single-centre, retrospective study. ( Aguilar-Mena, C; Bonifaz, A; Hernández-Salgado, Y; Rodriguez-Mendoza, A; Tirado-Sánchez, A, 2021) |
| "The present study determined effects of thalidomide on three successive generations of New Zealand White rabbits after oral dosing to F0 maternal rabbits during the later third of gestation (post major organogenesis) and lactation." | 1.32 | Effects of thalidomide on developmental, peri- and postnatal function in female New Zealand white rabbits and offspring. ( Denny, KH; Hoberman, AM; Morseth, S; Stirling, DI; Teo, SK; Thomas, SD, 2004) |
| "Thalidomide therapy was shown to be effective in numerous dermatologic diseases." | 1.29 | Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. ( Bastuji-Garin, S; Gherardi, R; Ochonisky, S; Revuz, J; Verroust, J, 1994) |
| "Thalidomide is a very effective drug in CDLE, but in most cases it exerts its effect only whilst treatment is continued." | 1.27 | Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. ( Bonsmann, G; Happle, R; Knop, J; Ludolph, A; Macher, E; Matz, DR; Mifsud, EJ, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (21.05) | 18.7374 |
| 1990's | 6 (15.79) | 18.2507 |
| 2000's | 9 (23.68) | 29.6817 |
| 2010's | 12 (31.58) | 24.3611 |
| 2020's | 3 (7.89) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, L | 1 |
| Xu, G | 1 |
| Wahab, A | 1 |
| Rafae, A | 1 |
| Faisal, MS | 1 |
| Mushtaq, K | 1 |
| Ehsan, H | 1 |
| Khakwani, M | 1 |
| Ashraf, A | 1 |
| Rehan, T | 1 |
| Ahmed, Z | 1 |
| Shah, Z | 1 |
| Khan, A | 1 |
| Anwer, F | 1 |
| Tirado-Sánchez, A | 1 |
| Aguilar-Mena, C | 1 |
| Rodriguez-Mendoza, A | 1 |
| Hernández-Salgado, Y | 1 |
| Bonifaz, A | 1 |
| Gruson, B | 1 |
| Lortholary, O | 1 |
| Canioni, D | 1 |
| Chandesris, O | 1 |
| Lanternier, F | 1 |
| Bruneau, J | 1 |
| Grosbois, B | 1 |
| Livideanu, C | 1 |
| Larroche, C | 1 |
| Durieu, I | 1 |
| Barete, S | 1 |
| Sevestre, H | 1 |
| Diouf, M | 1 |
| Chaby, G | 1 |
| Marolleau, JP | 1 |
| Dubreuil, P | 1 |
| Hermine, O | 1 |
| Damaj, G | 1 |
| Morabito, F | 1 |
| Bringhen, S | 2 |
| Larocca, A | 1 |
| Wijermans, P | 1 |
| Victoria Mateos, M | 1 |
| Gimsing, P | 1 |
| Mazzone, C | 1 |
| Gottardi, D | 1 |
| Omedè, P | 1 |
| Zweegman, S | 1 |
| José Lahuerta, J | 1 |
| Zambello, R | 1 |
| Musto, P | 1 |
| Magarotto, V | 1 |
| Schaafsma, M | 1 |
| Oriol, A | 1 |
| Juliusson, G | 1 |
| Cerrato, C | 1 |
| Catalano, L | 1 |
| Gentile, M | 1 |
| Isabel Turel, A | 1 |
| Marina Liberati, A | 1 |
| Cavalli, M | 1 |
| Rossi, D | 1 |
| Passera, R | 1 |
| Rosso, S | 1 |
| Beksac, M | 1 |
| Cavo, M | 1 |
| Waage, A | 1 |
| San Miguel, J | 1 |
| Boccadoro, M | 1 |
| Sonneveld, P | 1 |
| Palumbo, A | 2 |
| Offidani, M | 1 |
| Shen, P | 1 |
| Thomas, CR | 1 |
| Fenstermaker, J | 1 |
| Aklilu, M | 1 |
| McCoy, TP | 1 |
| Levine, EA | 1 |
| Devos, T | 1 |
| Thiessen, S | 1 |
| Cuyle, PJ | 1 |
| Meersseman, W | 1 |
| Delforge, M | 1 |
| Morrison, VA | 1 |
| Jung, SH | 1 |
| Johnson, J | 1 |
| LaCasce, A | 1 |
| Blum, KA | 1 |
| Bartlett, NL | 1 |
| Pitcher, BN | 1 |
| Cheson, BD | 1 |
| Vij, R | 1 |
| Fourcade, C | 1 |
| Mauboussin, JM | 1 |
| Lechiche, C | 1 |
| Lavigne, JP | 1 |
| Sotto, A | 1 |
| Hyakkoku, K | 1 |
| Nakajima, Y | 1 |
| Izuta, H | 1 |
| Shimazawa, M | 1 |
| Yamamoto, T | 1 |
| Shibata, N | 1 |
| Hara, H | 1 |
| Wang, M | 1 |
| Delasalle, K | 1 |
| Giralt, S | 1 |
| Alexanian, R | 1 |
| Gertz, MA | 1 |
| Tomás, JF | 1 |
| Giraldo, P | 1 |
| Lecumberri, R | 1 |
| Nistal, S | 1 |
| Mangiacavalli, S | 1 |
| Albani, G | 1 |
| Caravita, T | 1 |
| Cocito, F | 1 |
| Pascutto, C | 1 |
| Zappasodi, P | 1 |
| Cazzola, M | 1 |
| Corso, A | 1 |
| Rigual, D | 1 |
| Qiu, J | 1 |
| Fenstermaker, RA | 1 |
| Fabiano, AJ | 1 |
| Richardson, PG | 1 |
| Schlossman, RL | 1 |
| Weller, E | 1 |
| Hideshima, T | 1 |
| Mitsiades, C | 1 |
| Davies, F | 1 |
| LeBlanc, R | 1 |
| Catley, LP | 1 |
| Doss, D | 1 |
| Kelly, K | 1 |
| McKenney, M | 1 |
| Mechlowicz, J | 1 |
| Freeman, A | 1 |
| Deocampo, R | 1 |
| Rich, R | 1 |
| Ryoo, JJ | 1 |
| Chauhan, D | 1 |
| Balinski, K | 1 |
| Zeldis, J | 1 |
| Anderson, KC | 1 |
| Cavenagh, JD | 1 |
| Oakervee, H | 1 |
| Crawford, CL | 5 |
| Alfadley, A | 1 |
| Al-Rayes, H | 1 |
| Hussein, W | 1 |
| Al-Dalaan, A | 1 |
| Al-Aboud, K | 1 |
| Brocvielle, H | 1 |
| Muret, P | 1 |
| Plenat, E | 1 |
| Kantelip, JP | 1 |
| Humbert, P | 1 |
| Teo, SK | 1 |
| Denny, KH | 1 |
| Stirling, DI | 1 |
| Thomas, SD | 1 |
| Morseth, S | 1 |
| Hoberman, AM | 1 |
| Bamias, A | 1 |
| Dimopoulos, MA | 1 |
| Høyer, H | 1 |
| Wulff, CH | 1 |
| Asboe-Hansen, G | 1 |
| Brodthagen, H | 1 |
| Knop, J | 1 |
| Bonsmann, G | 1 |
| Happle, R | 1 |
| Ludolph, A | 1 |
| Matz, DR | 1 |
| Mifsud, EJ | 1 |
| Macher, E | 1 |
| Ochonisky, S | 1 |
| Verroust, J | 1 |
| Bastuji-Garin, S | 1 |
| Gherardi, R | 1 |
| Revuz, J | 1 |
| Stevens, RJ | 1 |
| Andujar, C | 1 |
| Edwards, CJ | 1 |
| Ames, PR | 1 |
| Barwick, AR | 1 |
| Khamashta, MA | 1 |
| Hughes, GR | 1 |
| Hamuryudan, V | 1 |
| Mat, C | 1 |
| Saip, S | 1 |
| Ozyazgan, Y | 1 |
| Siva, A | 1 |
| Yurdakul, S | 1 |
| Zwingenberger, K | 1 |
| Yazici, H | 1 |
| Clark, TE | 1 |
| Edom, N | 1 |
| Larson, J | 1 |
| Lindsey, LJ | 1 |
| Sobue, I | 1 |
| Gutiérrez-Rodríguez, O | 1 |
| Starusta-Bacal, P | 1 |
| Gutiérrez-Montes, O | 1 |
| Ranselaar, CG | 1 |
| Boone, RM | 1 |
| Kluin-Nelemans, HC | 1 |
| O'Sullivan, DJ | 1 |
| Swallow, M | 1 |
| DeFeo, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839] | Phase 2 | 21 participants (Actual) | Interventional | 2012-02-22 | Completed | ||
| A Multicenter, Open Label Study of Oral Melphalan, Prednisone, and CC-5013 (Revlimid) (MPR) as Induction Therapy in Elderly Newly Diagnosed Multiple Myeloma Patients[NCT00396045] | Phase 1/Phase 2 | 54 participants | Interventional | 2005-01-31 | Completed | ||
| A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma[NCT02906332] | Phase 2 | 12 participants (Actual) | Interventional | 2016-12-12 | Terminated (stopped due to FDA Hold Due to Updated Risks) | ||
| QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression[NCT00480363] | Phase 3 | 120 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma[NCT01042704] | Phase 1 | 29 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma[NCT04009109] | Phase 2 | 188 participants (Anticipated) | Interventional | 2020-10-21 | Recruiting | ||
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus[NCT00001680] | Phase 2 | 17 participants | Interventional | 1997-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 45 |
Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 95 |
Assessed by the investigator per International Myeloma Working Group criteria(IMWG) uniform response criteria. Result reflects number of participants whose best overall response qualified as sCR, CR, or VGPR in 2 year follow up period. (NCT02906332)
Timeframe: Every 3 weeks (day 1 of every 21-day treatment cycle +/- 7 days) through 12 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 11 |
Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received pembrolizumab (MK-3475), lenalidomide and dexamethasone, including serious adverse events (SAEs). Result reflects count of participants who experienced an SAE. (NCT02906332)
Timeframe: Up to 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 1 |
Assessed at 12 months; Subjects without documented PD or death will be censored at the last disease assessment date. Those who died without documented PD will be censored at the time of death. Result reflects count of participants who had progressed at 12 months. (NCT02906332)
Timeframe: Time from Day 0 (transplant) and date of enrollment to study completion (through 12 weeks) by investigator assessment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 10 |
PFS will be assessed from the date of ASCT, with day 0 defined as date of stem cell infusion (if tandem transplant the 2nd of 2 transplants will be used) until the date of progression, defined as the date at which the patient starts the next line of therapy or the date of death. (NCT02906332)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Lenalidomide | 27.6 |
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
7 reviews available for thalidomide and Nervous System Disorders
| Article | Year |
|---|---|
The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases.
Topics: Adaptor Proteins, Signal Transducing; Animals; Humans; Immunomodulating Agents; Ligands; Neoplasms; | 2022 |
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney; Multiple Myeloma; Nervous System D | 2011 |
[Management of a patient receiving thalidomide].
Topics: Abnormalities, Drug-Induced; Adult; Female; France; Humans; Immunosuppressive Agents; Male; Monitori | 2003 |
Thalidomide and immunomodulatory drugs in the treatment of cancer.
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Neoplasms; Nervous System Diseases; Thalidomide | 2005 |
Use of thalidomide in leprosy.
Topics: Erythema Nodosum; Humans; Leprosy; Nervous System Diseases; Peripheral Nervous System; Thalidomide | 1994 |
Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.
Topics: Angiogenesis Inhibitors; Anti-HIV Agents; Drug Labeling; Erythema Nodosum; Female; Hallucinations; H | 2001 |
[Exogenous toxic neuropathy (author's transl)].
Topics: Acrylamides; Adolescent; Adult; Aged; Aldrin; Carbon Disulfide; Chloramphenicol; Clioquinol; DDT; Di | 1976 |
6 trials available for thalidomide and Nervous System Disorders
| Article | Year |
|---|---|
Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.
Topics: Adult; Aged; Bone Marrow; Fatigue; Female; Fever; Gastrointestinal Diseases; Hematologic Diseases; H | 2013 |
Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Appendiceal Neoplasms; | 2014 |
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease- | 2015 |
Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration | 2012 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Behcet Syndrome; Double-Blind Method; Drug Administration Schedule; Follow-Up Stu | 1998 |
25 other studies available for thalidomide and Nervous System Disorders
| Article | Year |
|---|---|
Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials a | 2020 |
Clinical-therapeutic study on the efficacy and safety of thalidomide in the management of discoid lupus erythematosus. A single-centre, retrospective study.
Topics: Adult; Dermatologic Agents; Humans; Immunosuppressive Agents; Lupus Erythematosus, Discoid; Male; Mi | 2021 |
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2014 |
Long-term follow-up in a patient with the dermato-neuro syndrome treated with high-dose melphalan, thalidomide, and intravenous immunoglobulins for more than 7 years.
Topics: Adult; Follow-Up Studies; Humans; Immunoglobulins, Intravenous; Male; Melphalan; Nervous System Dise | 2014 |
Thalidomide in the treatment of immune reconstitution inflammatory syndrome in HIV patients with neurological tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active | 2014 |
Thalidomide protects against ischemic neuronal damage induced by focal cerebral ischemia in mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Analysis of Variance; Animals; Blood Pressure; Cell Death; Cells, Cultu | 2009 |
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2010 |
Reducing neurotoxicity in the management of multiple myeloma.
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Multiple Myeloma; Nervous System Diseases; Salva | 2011 |
POEMS syndrome with severe neurological damage clinically recovered with lenalidomide.
Topics: Adult; Aged; Female; Humans; Lenalidomide; Male; Middle Aged; Nervous System Diseases; POEMS Syndrom | 2012 |
Tumoral Bing-Neel Syndrome presenting as a cerebellar mass.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplas | 2013 |
Thalidomide in multiple myeloma: current status and future prospects.
Topics: Abnormalities, Drug-Induced; Adjuvants, Immunologic; Angiogenesis Inhibitors; Antineoplastic Combine | 2003 |
The schizophrenic career of a "monster drug".
Topics: Dapsone; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy; Leprosy, Lepromatous; Nervous System | 2003 |
Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus.
Topics: Adult; Dermatologic Agents; Dose-Response Relationship, Drug; Humans; Lupus Erythematosus, Discoid; | 2003 |
Effects of thalidomide on developmental, peri- and postnatal function in female New Zealand white rabbits and offspring.
Topics: Abnormalities, Drug-Induced; Abortifacient Agents; Animals; Animals, Newborn; Body Weight; Dose-Resp | 2004 |
[Treatment of prurigo nodularis Hyde with thalidomide].
Topics: Aged; Female; Humans; Male; Middle Aged; Nervous System Diseases; Prurigo; Thalidomide | 1983 |
Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus.
Topics: Chronic Disease; Female; Follow-Up Studies; Humans; Lupus Erythematosus, Discoid; Male; Nervous Syst | 1983 |
Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus.
Topics: Chronic Disease; Female; Follow-Up Studies; Humans; Lupus Erythematosus, Discoid; Male; Nervous Syst | 1983 |
Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus.
Topics: Chronic Disease; Female; Follow-Up Studies; Humans; Lupus Erythematosus, Discoid; Male; Nervous Syst | 1983 |
Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus.
Topics: Chronic Disease; Female; Follow-Up Studies; Humans; Lupus Erythematosus, Discoid; Male; Nervous Syst | 1983 |
Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients.
Topics: Adult; Aged; Electrophysiology; Female; Humans; Incidence; Male; Middle Aged; Nervous System Disease | 1994 |
Thalidomide neuropathy.
Topics: Humans; Leprostatic Agents; Nervous System Diseases; Thalidomide | 1996 |
Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.
Topics: Adult; Drug Tolerance; Female; Humans; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Nervous Sy | 1997 |
Use of thalidomide in leprosy.
Topics: Humans; Leprosy; Nervous System Diseases; Thalidomide | 1991 |
Thalidomide and leprosy.
Topics: Humans; Leprosy; Nervous System Diseases; Thalidomide | 1985 |
Thalidomide-induced neuropathy in rheumatoid arthritis patients.
Topics: Arthritis, Rheumatoid; Female; Humans; Nervous System Diseases; Thalidomide | 1988 |
Thalidomide in the treatment of neuro-Behçet's syndrome.
Topics: Adult; Behcet Syndrome; Chlorambucil; Drug Therapy, Combination; Humans; Male; Nervous System Diseas | 1986 |
The fibre size and content of the radial and sural nerves.
Topics: Adolescent; Adult; Age Factors; Aged; Alcoholism; Extremities; Female; Humans; Male; Middle Aged; My | 1968 |
Hansenosis of the neurotrophic type.
Topics: Adult; Fever; Humans; Leprosy; Male; Nervous System Diseases; Skin; Sulfones; Thalidomide | 1969 |